MA50353A - Anticorps ciblant pdl1 et procédés d'utilisation associés - Google Patents

Anticorps ciblant pdl1 et procédés d'utilisation associés

Info

Publication number
MA50353A
MA50353A MA050353A MA50353A MA50353A MA 50353 A MA50353 A MA 50353A MA 050353 A MA050353 A MA 050353A MA 50353 A MA50353 A MA 50353A MA 50353 A MA50353 A MA 50353A
Authority
MA
Morocco
Prior art keywords
pdl1
associated methods
targeting antibodies
targeting
antibodies
Prior art date
Application number
MA050353A
Other languages
English (en)
French (fr)
Inventor
Matthias Brock
Tea Gunde
Christian Hess
Alexandre Simonin
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195781.4A external-priority patent/EP3470429A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50353A publication Critical patent/MA50353A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Liquid Crystal Substances (AREA)
MA050353A 2017-10-10 2018-10-09 Anticorps ciblant pdl1 et procédés d'utilisation associés MA50353A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17195781.4A EP3470429A1 (en) 2017-10-10 2017-10-10 Antibodies targeting pdl1 and methods of use thereof
EP18167094 2018-04-12
EP18180816 2018-06-29

Publications (1)

Publication Number Publication Date
MA50353A true MA50353A (fr) 2020-08-19

Family

ID=63834022

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050353A MA50353A (fr) 2017-10-10 2018-10-09 Anticorps ciblant pdl1 et procédés d'utilisation associés

Country Status (11)

Country Link
US (2) US12077588B2 (enExample)
EP (1) EP3694879A1 (enExample)
JP (3) JP7791650B2 (enExample)
KR (2) KR20200063147A (enExample)
CN (2) CN120248120A (enExample)
AU (2) AU2018348430B2 (enExample)
CA (1) CA3074802A1 (enExample)
IL (2) IL273578B2 (enExample)
MA (1) MA50353A (enExample)
SG (1) SG11202001654TA (enExample)
WO (1) WO2019072869A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709418B (zh) * 2017-06-05 2023-09-26 努玛治疗有限公司 新型抗hsa抗体
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
SG11202103000WA (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
PE20260551A1 (es) * 2023-05-19 2026-03-04 Numab Therapeutics AG Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida
IL328540A (en) 2023-12-22 2026-07-01 Numab Therapeutics AG Antibody binding complexes specific for LILRB2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
ES2367430T3 (es) * 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2911946A1 (en) * 2013-05-10 2014-11-13 Numab Ag Bispecific constructs and their use in the treatment of various diseases
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
KR102317479B1 (ko) * 2017-05-05 2021-10-26 노키아 테크놀로지스 오와이 무선 링크 제어 상태 보고

Also Published As

Publication number Publication date
JP7791650B2 (ja) 2025-12-24
JP2023166403A (ja) 2023-11-21
CN120248120A (zh) 2025-07-04
IL273578B1 (en) 2025-11-01
KR20200063147A (ko) 2020-06-04
JP2021501569A (ja) 2021-01-21
IL323510A (en) 2025-11-01
US20250066482A1 (en) 2025-02-27
JP7874215B2 (ja) 2026-06-15
CN111225926A (zh) 2020-06-02
US12077588B2 (en) 2024-09-03
CA3074802A1 (en) 2019-04-18
JP7649825B2 (ja) 2025-03-21
EP3694879A1 (en) 2020-08-19
KR20250057935A (ko) 2025-04-29
IL273578A (en) 2020-05-31
AU2025271488A1 (en) 2026-01-08
IL273578B2 (en) 2026-03-01
US20200283528A1 (en) 2020-09-10
WO2019072869A1 (en) 2019-04-18
AU2018348430A1 (en) 2020-03-12
SG11202001654TA (en) 2020-03-30
AU2018348430B2 (en) 2025-09-04
JP2025102791A (ja) 2025-07-08
CN111225926B (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
FR24C1050I1 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3731867A4 (en) Anti-lrp5/6 antibodies and methods of use
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3797123A4 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
EP3710589A4 (en) ANTI-C1S ANTIBODIES AND METHOD OF USING
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3472200A4 (en) ANTI-MYOSTATIN ANTIBODIES AND METHOD FOR USE
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3436476A4 (en) ANTI-RYK ANTIBODIES AND METHOD FOR USE THEREOF
EP3383913A4 (en) ANTIBODY AGAINST FC RECEPTOR LIKE 5 AND METHOD OF USE
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA45671A (fr) Anticorps antivirus zika et procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3472316A4 (en) ANTI-C5 ANTIBODIES AND METHOD FOR USE
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
EP3684819A4 (en) Anti-ykl40 antibodies and methods of use
EP3491025A4 (en) FCRN ANTIBODIES AND METHOD FOR USE THEREOF